Deepika Khedekar, Associate Centralized Clinical Trial Lead at IQVIA Inc, looks at the challenges of utilising artificial intelligence (AI) in oncology clinical research. Ten million1 people around the world die from cancer each year. Yet, while the number of cancer clinical trials has soared from 19,211… Read More
Traditional drug discovery is time-consuming and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join DDW and FUJIFILM Wako on 24 May 3PM BST to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new… Read More
Fiona Maini, Senior Director Global Compliance & Strategy, at Medidata looks at the rise of artificial intelligence (AI) and machine learning (ML) within life sciences and the applications for the technology in clinical trials. The benefits that AI and machine learning (ML) can bring to society and their potential to… Read More
Traditional drug discovery is time-consuming and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join DDW and FUJIFILM Wako on 24 May 3PM BST to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new… Read More
DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Many of the best-selling drugs in 2023 were monoclonal antibody (mAB) therapies, including Keytruda (pembrolizumab), Humira (adalimumab), and Dupixent (dupilumab)1. This won’t come as a surprise when you… Read More
Traditional drug discovery is time-consuming, and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join DDW and FUJIFILM Wako on 24 May 3PM BST to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new… Read More
BenevolentAI has announced it will be reducing headcount by around 30% and closing its US office as part of a change of focus in its business priorities. The company says it will focus on its AI-driven drug discovery collaboration and proprietary pipeline, believing these will bring… Read More
Xaira Therapeutics, a joint incubation by ARCH Venture Partners and Foresite Labs, has launched with more than $1 billion of committed capital from lead investors. Xaira is building a platform for drug discovery and development that it hopes will advance multiple drug programmes and unlock biological… Read More
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has supported the use of artificial intelligence (AI) to deliver benefit for patients, life science companies and society, in response to the EU Artificial Intelligence (AI) Act. The AI Act, which bans certain AI applications that it… Read More
Antiverse is an artificial intelligence (AI)-driven company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Murat Tunaboylu, Co-founder and CEO of Antiverse, speaks with Megan Thomas about how AI can advance therapeutic antibody design. Megan T: How is Antiverse using… Read More
Traditional drug discovery is time-consuming, and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join DDW and FUJIFILM Wako on 24 May 3PM BST to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new… Read More
Reece Armstrong speaks to Sean McClain, Founder & CEO of Absci, about the rise of generative AI in life sciences. The company has a biologics pipeline with a focus on differentiated antibodies targeting a range of indications. Last year, a lot of focus was placed on artificial intelligence… Read More
Rob Scoffin, CEO, and Matthew Habgood, Principal Computational Chemistry Developer at Cresset, discuss the role of AI/ML in advancing screening methods by utilising virtual screening (VS) approaches to process compound libraries on an ultra-large scale. Drug discovery is a complex process that relies on designing and… Read More
Recursion has announced plans to open a new office in June 2024. The site will provide Recursion and Valence Labs, the company’s artificial intelligence (AI) research engine, with access to European talent and a life science ecosystem from which to work. Chris Gibson, Co-founder and CEO… Read More
Elsevier and Iktos have partnered to strengthen Elsevier’s chemistry solution, Reaxys, by combining the company’s chemistry data with synthetic planning AI technologies developed by Iktos. The partnership aims to support R&D organisations to decrease the time required to complete Design-Make-Test-Analyse cycles of small molecules, thus reducing… Read More
Research published in Cell Genomics has shown that prostate cancer includes two different subtypes of the disease, also known as evotypes. This discovery was made by using artificial intelligence (AI) to help unlock new discoveries about the evolution of prostate cancer and could lead to the… Read More
